SG11201908512YA - Somatostatin modulators and uses thereof - Google Patents

Somatostatin modulators and uses thereof

Info

Publication number
SG11201908512YA
SG11201908512YA SG11201908512YA SG11201908512YA SG 11201908512Y A SG11201908512Y A SG 11201908512YA SG 11201908512Y A SG11201908512Y A SG 11201908512YA SG 11201908512Y A SG11201908512Y A SG 11201908512YA
Authority
SG
Singapore
Prior art keywords
international
california
cornerstone
court
suite
Prior art date
Application number
Other languages
English (en)
Inventor
Sangdon Han
Sun Hee Kim
Yunfei Zhu
Original Assignee
Crinetics Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crinetics Pharmaceuticals Inc filed Critical Crinetics Pharmaceuticals Inc
Publication of SG11201908512YA publication Critical patent/SG11201908512YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
SG11201908512Y 2017-03-16 2018-03-15 Somatostatin modulators and uses thereof SG11201908512YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762472480P 2017-03-16 2017-03-16
PCT/US2018/022665 WO2018170284A1 (fr) 2017-03-16 2018-03-15 Modulateurs de la somatostatine et leurs utilisations

Publications (1)

Publication Number Publication Date
SG11201908512YA true SG11201908512YA (en) 2019-10-30

Family

ID=63523267

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908512Y SG11201908512YA (en) 2017-03-16 2018-03-15 Somatostatin modulators and uses thereof

Country Status (16)

Country Link
US (1) US11072598B2 (fr)
EP (1) EP3596062A4 (fr)
JP (1) JP7106564B2 (fr)
KR (1) KR20190121404A (fr)
CN (1) CN110650951B (fr)
AU (1) AU2018234806A1 (fr)
BR (1) BR112019019168A2 (fr)
CA (1) CA3056131A1 (fr)
EA (1) EA201992083A1 (fr)
IL (1) IL269241B (fr)
MX (1) MX2019010949A (fr)
NZ (1) NZ757081A (fr)
SG (1) SG11201908512YA (fr)
TW (1) TW201840550A (fr)
UA (1) UA127346C2 (fr)
WO (1) WO2018170284A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201992083A1 (ru) 2017-03-16 2020-03-18 Кринетикс Фармасьютикалс, Инк. Модуляторы соматостатина и их применения
MA51840A (fr) * 2018-02-12 2021-05-19 Crinetics Pharmaceuticals Inc Modulateurs de somatostatine et leurs utilisations
WO2019240246A1 (fr) * 2018-06-15 2019-12-19 小野薬品工業株式会社 Nouveaux sels et nouvelles formes cristallines de dérivés de pipéridinol
US10696689B2 (en) * 2018-09-18 2020-06-30 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
CN114585614A (zh) 2019-08-14 2022-06-03 克林提克斯医药股份有限公司 非肽促生长素抑制素5型受体激动剂及其用途
WO2021076448A1 (fr) * 2019-10-14 2021-04-22 Crinetics Pharmaceuticals, Inc. Modulateurs de somatostatine pour le traitement d'adénomes pituitaires
KR20230066379A (ko) 2020-09-09 2023-05-15 크리네틱스 파마슈티칼스, 인크. 소마토스타틴 조절제 제형
CA3207378A1 (fr) 2021-02-17 2022-08-25 Yuxin Zhao Formes cristallines d'un modulateur de la somatostatine
EP4351654A1 (fr) * 2021-06-09 2024-04-17 Crinetics Pharmaceuticals, Inc. Agents thérapeutiques ciblés non peptidiques et leurs utilisations
CN114591326B (zh) * 2022-02-28 2024-02-27 上海筛杰生物医药有限公司 Cct-251921的中间体及其制备方法
WO2024089668A1 (fr) * 2022-10-28 2024-05-02 Basecamp Bio Inc. Agonistes du récepteur 2 de la somatostatine et leurs utilisations

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127343A (en) 1996-05-14 2000-10-03 Novo Nordisk A/S Somatostatin agonists and antagonists
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
FR2802206B1 (fr) 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
US20060281764A1 (en) * 2005-06-10 2006-12-14 Gaul Michael D Aminopyrimidines as kinase modulators
JP2009530276A (ja) 2006-03-13 2009-08-27 メルク エンド カムパニー インコーポレーテッド ソマトスタチンアゴニスト
KR101117931B1 (ko) 2006-08-15 2012-04-12 에프. 호프만-라 로슈 아게 페닐, 피리딘 및 퀴놀린 유도체
EP2211619A1 (fr) 2007-10-18 2010-08-04 Merck Sharp & Dohme Corp. 1,2,4-oxadiazoles substitués et leurs analogues comme modulateurs des récepteurs cb2, utiles dans le traitement de la douleur et de maladies respiratoires et non respiratoires
WO2009158467A2 (fr) 2008-06-25 2009-12-30 Envivo Pharmaceuticals, Inc. Composés phényles disubstitués
GB0818241D0 (en) 2008-10-06 2008-11-12 Cancer Res Technology Compounds and their use
WO2011027249A2 (fr) * 2009-09-01 2011-03-10 Pfizer Inc. Dérivés de benzimidazole
CA2799414A1 (fr) 2010-05-18 2011-11-24 Merck Sharp & Dohme Corp. Composes spiroisoxazolines en tant qu'antagonistes sstr5
GB201008290D0 (en) 2010-05-18 2010-06-30 Syngenta Ltd Chemical compounds
JP2014007228A (ja) 2012-06-22 2014-01-16 Ps4 Luxco S A R L 半導体装置及びその製造方法
EP2871179A4 (fr) 2012-07-03 2016-03-16 Ono Pharmaceutical Co Composé ayant une activité agoniste sur un récepteur de la somatostatine, et leur utilisation à des fins médicales
JP2015046482A (ja) 2013-08-28 2015-03-12 住友電気工業株式会社 半導体装置およびモジュール
WO2015046482A1 (fr) * 2013-09-30 2015-04-02 小野薬品工業株式会社 Composé ayant une activité agoniste sur les récepteurs de la somatostatine et son utilisation médicale
US10093795B2 (en) 2013-10-02 2018-10-09 Kuraray Co., Ltd. Resin composition, multilayer sheet, packaging material and container
EP3484865B1 (fr) 2016-07-14 2022-09-14 Crinetics Pharmaceuticals, Inc. Modulateurs de la somatostatine et leurs utilisations
RU2019124888A (ru) 2017-02-08 2021-03-10 Оно Фармасьютикал Ко., Лтд. Соединение, имеющее агонистическую активность в отношении рецептора соматостатина, и его фармацевтическое применение
EA201992083A1 (ru) 2017-03-16 2020-03-18 Кринетикс Фармасьютикалс, Инк. Модуляторы соматостатина и их применения
US11028068B2 (en) 2017-07-25 2021-06-08 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
MA51840A (fr) 2018-02-12 2021-05-19 Crinetics Pharmaceuticals Inc Modulateurs de somatostatine et leurs utilisations
US10696689B2 (en) 2018-09-18 2020-06-30 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof

Also Published As

Publication number Publication date
EA201992083A1 (ru) 2020-03-18
MX2019010949A (es) 2019-10-24
CA3056131A1 (fr) 2018-09-20
TW201840550A (zh) 2018-11-16
UA127346C2 (uk) 2023-07-26
BR112019019168A2 (pt) 2020-04-14
EP3596062A1 (fr) 2020-01-22
IL269241A (en) 2019-11-28
NZ757081A (en) 2023-03-31
JP2020511452A (ja) 2020-04-16
US11072598B2 (en) 2021-07-27
AU2018234806A1 (en) 2019-10-03
WO2018170284A1 (fr) 2018-09-20
IL269241B (en) 2022-09-01
JP7106564B2 (ja) 2022-07-26
US20200010453A1 (en) 2020-01-09
EP3596062A4 (fr) 2020-08-26
CN110650951B (zh) 2023-02-24
CN110650951A (zh) 2020-01-03
KR20190121404A (ko) 2019-10-25

Similar Documents

Publication Publication Date Title
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201906200WA (en) Nucleic acid-polypeptide compositions and methods of inducing exon skipping
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201811232XA (en) Treatment of amd using aav2 variant with aflibercept
SG11201808990QA (en) Compositions for topical application of compounds
SG11201809627QA (en) Anti pd-1 and anti-lag3 antibodies for cancer treatment
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201903167QA (en) Compounds and methods for reducing atxn3 expression
SG11201909011PA (en) Niraparib compositions
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201809751XA (en) Egfr inhibitor compounds
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201903312VA (en) Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds